

























































DPP-4 Cleaves α/β-Peptide Bonds: Substrate Specificity and
Half-Lives
Amila Turalić,[a] Jasmina Đeđibegović,[a] Zsófia Hegedüs,*[b] and Tamás A. Martinek*[b, c]
The incorporation of β-amino acids into a peptide sequence has
gained particular attention as β- and α/β-peptides have shown
remarkable proteolytic stability, even after a single homologa-
tion at the scissile bond. Several peptidases have been shown
to cleave such bonds with high specificity but at a much slower
rate compared to α-peptide bonds. In this study, a series of
analogs of dipeptidyl peptidase-4 (DPP-4) substrate inhibitors
were synthesized in order to investigate whether β-amino acid
homologation at the scissile bond could be a valid approach to
improving peptide stability towards DPP-4 degradation. DPP-4
cleaved the α/β-peptide bond after the N-terminal penultimate
Pro with a broad specificity and retained full activity regardless
of the β3-amino acid side chain and peptide length. Significantly
improved half-lives were observed for β3Ile-containing peptides.
Replacing the penultimate Pro with a conformationally con-
strained Pro mimetic led to proteolytic resistance. DPP-4
cleavage of α/β-peptide bonds with a broad promiscuity
represents a new insight into the stability of peptide analogs
containing β-amino acids as such analogs were thought to be
stable towards enzymatic degradation.
Introduction
Rapid proteolytic degradation of peptides by endogenous
enzymes is one of the major obstacles to their application in
humans.[1] Peptide backbone modification by introduction of
unnatural amino acids is an effective method for preparation of
stable and peptidase resistant peptide analogs, without altering
their activity. Of many unnatural amino acids known, β-amino
acids gained much attention. Oligomers built from β-amino
acids show tendency to adopt well-defined structures[2,3]
capable of exerting biological function and having increased
proteolytic stability at the same time.[3,4] β-Peptides have been
shown to have remarkable stability against a wide range of
proteases[5–8] which can be explained by changes of the
electronic environment around the amide bond or lack of
substrate recognition resulting from the altered side-chain
spacing or conformation of the peptide backbone.[9,10]
Besides pure β-peptides, it has been shown that α/β-
peptides in which the β-amino acid replacement does not
change the relative orientation of side chains around the scissile
bond (Scheme 1), thus mimicking α-peptide environment, are
still stable against a wide range of proteases.[9] This was
confirmed by many examples of peptide analogs where a
strategic replacement of a single P1’ amino acid by a β-
homolog (Scheme 1b) abolished the activity of pepsin, chymo-
trypsin, plasmepsin II,[11] metalloproteinase EP24.15 and
EP24.16,[12] neprylisin,[13] pronase E[14] or ACE-2,[15] and improved
the stability of the whole peptide. With this kind of substitution,
minimal modifications are possible in order to provide peptide
stability, while maintaining α-peptide structural and spatial
characteristics required for interaction with receptor.
Reports on α/β-bond cleavage are not unprecedented.
Pronase, a mixture of fungal endo- and exopeptidases could
cleave the N-terminal Ala-β3Ala peptide bond although with a
much slower rate in comparison with the natural sequence and
it was attributed to its exopeptidase activity.[9] In the same
study, pronase did not cleave Arg-β3Ala or after N-terminal
βGly, pointing towards this is not a general feature of the
enzyme. Angiotensin-converting enzyme cleaved α/β-peptide
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Scheme 1. (a) Natural α-peptide bond and (b-d) three types of homologation
using β2 (side chain on the second carbon atom) or β3 (side chain on the
third carbon atom) amino acids that do not change environment around the
peptide bond, thus mimicking an α-peptide environment: (b) αXaa-β3Xaa, (c)
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bond in substance P analog with β3- and β2Ala modification at
P1’, resulting in prolonged half-life of the analog,[16] but β-
peptidase activity was not later confirmed as well. Another
enzyme, proteinase K showed aminopeptidase activity on N-
terminal Val-Glu peptide bond when Val was replaced by β3-
homolog. Although cleaved, peptide half-life was increased
from 1.6 to 300 min.[17]
Since β-amino acids gained huge attention to produce
metabolically stable bioactive peptide analogs or enzyme
inhibitors,[18] it is important to understand which factors can
potentially influence their degradation in humans. This poses
the question whether enzymes that have broad substrate
specificity cleave certain α/β-peptide bonds or a single β-amino
acid subsitution at the cleavage site is sufficient to create stable
analogs. In the present study, the ability of the human
dipeptidyl peptidase-4 (DPP-4) to cleave α/β-peptides was
investigated with the primary aim of determining their stability
against such an enzyme.
DPP-4 is a human exopeptidase that can be found in
soluble circulating or membrane bound form and it is one of
the few enzymes that cleaves peptide bonds primarily after
Pro.[19] By cleaving dipeptides from N-terminus of proteins
and oligopeptides, DPP-4 regulates a variety of physiological
functions including immune regulation, endocrine activity
and degradation of peptide hormones.[20] Besides well-known
Xaa-Ala DPP-4 substrates GLP-1 and GIP, there are over 40
physiological and pharmacological substrates,[21] such as
neuropeptides (substance P, bradykinin, endomorphin-1,
neuropeptide Y, gastrin releasing peptide), gastric hormones
(PYY, enterostatin) various chemokines, brain natriuretic
peptide, erythropoietin, granulocyte colony-stimulating fac-
tor, and other various endogenous peptides with penultimate
(i. e., the next to last amino acid from the N-terminus) Pro in
their structure.[22–24] Thus, the investigation of β-amino acid
substitution after Pro could provide an insight for rational
design of peptidic analogs of these ligands.
Results
In order to investigate how different β-amino acid substitutions
at positions P1 and P1’ of DPP-4 substrates affect their stability,
following the substitution strategy shown in Scheme 1b, a
series of α/β-peptide analogs of known DPP-4 ligands were
synthesized (Scheme 2) and tested using an enzymatic cleavage
assay. Proline containing tripeptides IPI and VPL are among the
strongest known DPP-4 peptide inhibitors[25] whereas IPA and
IPM have been shown to have inhibitory activity as well.[26,27]
These peptides are also substrates for the enzyme hence acting
as competitive inhibitors, and their inhibitory activity is a result
of kinetic artefact.[28,29] Based on these sequences, tripeptides
having a general IPXaa structure were chosen as a model,
where Xaa can represent any amino acid side chain. All selected
tripeptides have Ile at position P2, in order to exclude possible
influence of different amino acids at this position on DPP-4
cleavage and preserve effective docking to the enzyme.
First, IPA, IPI and IPM were prepared by solid-phase peptide
synthesis and subjected to a DPP-4 cleavage test. The peptides
were incubated with the enzyme, and the amount of the intact
peptide and the cleavage products were determined by HPLC-
MS monitored for 24 h. The resulting degradation curves were
fitted to determine peptide half-lives (Figure 1a, Table 1,
Table S1 in the Supporting information).
In all three cases, the cleavage product IP could be
detected, showing that the cleavage occurs at the anticipated
site. The obtained half-lives of IPA, IPI and IPM were quite
similar (~5, 6 and 4 min respectively, Table 1), showing no
significant effect of the P1’ amino acid on the peptide
degradation.
In order to test whether β-amino acid replacement at
position P1’ of these peptides influence stability, the α/β-
analogs (IPβ3A, IPβ3I and IPβ3M) were synthesized and tested
following the same protocol. IPβ3A and IPβ3M showed only a
slightly increased resistance against DPP-4 cleavage, on the
other hand, for IPβ3I a significantly prolonged half-life (t1/2
~274 min) was observed compared to the natural sequence IPI
(t1/2 ~6 min) (Figure 1b, Tables 1 and S2). The sequence IP was
detected as a degradation product for all of the peptides,
pointing towards that DPP-4 is able to cleave the peptide bond
between the α-amino acid at P1 and the β3-amino acid at
position P1’, but the rate of cleavage is depending on the
nature of the amino acid side chain at P1’.
Scheme 2. DPP-4 ligands and the investigated α/β-peptide analogs. Sche-
matic figure of IPXaa series of peptides. (a) DPP-4 cleaves any peptide bond
after proline (highlighted grey), except for Pro at position P1’. Schematic
figure of α/β-peptides with (b) β3-amino acids, (c) cyclic β-amino acid
substitution at position P1’ and (d) Pro to cyclic β-amino acid substitution at
position P1.
Table 1. Approximate half-lives of α-peptides and corresponding α/β-





1 IPA 5 11 IPβ3S 6
2 IPI 6 12 IPβ3W 7
3 IPM 4 13 IP-(1S,2S)ACPC 12
4 IPβ3A 12 14 IPIQY 7
5 IPβ3I 274 15 IPβ3IQY 216
6 IPβ3M 8 16 LPQNIPPL 9
7 IPβ3E 15 17 LPβ3QNIPPL 27
8 IPβG 3 18 I-(1R,2R)ACPC-I >1440
9 IPβ3K 17 19 I-(1S,2S)ACPC-A >1440
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To further investigate the substrate specificity of DPP-4 for
α/β-peptide bond cleavage, a series of IPβ3Xaa tripeptides were
synthesized having all classes of amino acid side chains at P1’
namely β3E, βG, β3K, β3Q, β3S, β3W and a cyclic β-amino acid
(1S,2S)-aminocyclopentane-carboxylic acid (ACPC). Cleavage
product IP was observed for all of the tested peptides, with
almost no intact peptide after 1 h (Figure 2, Table S3), resulting
in similar half-lives (Table 1). Analogs having charged side
chains or ACPC showed a slightly increased stability in
comparison with the other sequences, with half-lives of
approximately 11–17 min. These results suggested that DPP-4
retains its broad side chain specificity for β3-amino acid
substitutions except for the bulky, hydrophobic β3Ile substitu-
tion, which slows down the cleavage significantly.
To investigate further this new insight into DPP-4 cleavage
of α/β-peptides, previously reported longer DPP-4 peptide
inhibitors IPIQY and LPQNIPPL and their analogs IPβ3IQY and
LPβ3QNIPPL were synthesized. Results of DPP-4 cleavage test
for these longer peptides were in correlation with the tripeptide
series. Cleavage products IP and LP, as well as IQY/β3IQY and
QNIPPL/β3QNIPPL were observed for tested α and α/β-peptide
analogs (Figure 3, Table S4). The β3Ile substitution had the same
profound effect on stability, while substitution with β3Gln
resulted only in 3-fold increase in half-life.
Further, we wanted to examine DPP-4 cleavage when Pro is
substituted with a Pro mimicking, conformationally constrained
Figure 1. DPP-4 degradation curves of (a) IPA, IPI and IPM and (b) β3-amino
acid-modified peptides. Remaining peptide quantities were determined
based on LCMS peak integration. Peptides (50 μM final concentration) were
incubated with DPP-4 in TBS buffer (pH 8.0) at 37 °C for 24 h. Curves were
fitted by using a one-phase exponential decay fit with a variable plateau
value y = (y0–yP) e
  kx + yP. Note that the x-axes cover a different range. Data
points show the average of two individual experiments, error bars represent
the standard deviation. In several cases the error bars are smaller than the
symbol size.
Figure 2. DPP-4 degradation curves of tripeptides of IPβ3Xaa series. Curves
were fitted by using a one-phase exponential decay fit with a variable
plateau value y = (y0–yP)e
  kx + yP. Data points show the average of two
individual experiments, error bars represent the standard deviation. In
several cases the error bars are smaller than the symbol size.
Figure 3. (a) DPP-4 degradation curves of IPIQY and IPβ3IQY and (b)
LPQNIPPL and LPβ3QNIPPL. Curves were fitted by using a one-phase
exponential decay fit with a variable plateau value y = (y0–yP)e
  kx + yP. Data
points show the average of two individual experiments, error bars represent
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β-amino acid ACPC. In contrast to other tested peptides with
α!β3 replacement after Pro, I-(1R,2R)ACPC-I, I-(1S,2S)ACPC-A
and I-(1R,2R)ACPC-A were stable to degradation by DPP-4, since
DPP-4 cleavage products were not observed within 24 h.
To demonstrate the unique ability of DPP-4 cleaving α/β-
peptide bonds we compared half-lives with a nonspecific
protease. The peptide LPQNIPPL and its α/β-analog LPβ3QNIPPL
were tested against a broad-spectrum serine protease protei-
nase K. Small peptides were excluded due to peptide size limits
for proteinase K cleavage.[30] LPQNIPPL was completely cleaved
within a few hours, with half-life of ~39 min (cleavage products
LPQ and NIPPL were observed), while LPβ3QNIPPL remained
stable, without any cleavage products observed within 24 h
(Figure 4, Table S5). This is consistent with previous studies[11]
demonstrating that the amino acid replacement at the cleavage
site abolishes proteinase K action which contrasts with the
activity of DPP-4 shown here.
Discussion
β-Amino acid replacement is a recognized strategy to obtain
metabolically stable analogs of bioactive peptides, thus it is
important to investigate every aspect of their metabolic route
in humans. Here we investigated the effect of a single β-amino
acid replacements in substrates of DPP-4, a human exopepti-
dase playing the key role in a wide variety of physiological
functions.[20]
The main cleavage product of the IPβXaa ligand series was the
IP sequence, indicating that DPP-4 is one of the few enzymes that
can cleave a bond between an α and a β-amino acid. Known β-
aminopeptidases in humans cleave only a specific bond, such as
the βAla/His bond in case of carnosinase.[31,32] In contrast, our
results indicate that the cleavage specificity of DPP-4 for an α/β-
bond is not limited to certain residues, thus DPP-4 is the only
human peptidase that have a broad substrate specificity for α/β-
bond cleavage and is able to retain its full activity, when a β-
amino acid is present at P1’.
It has been shown that DPP-4 does not have a strong
preference for amino acids at P1’, and is capable of cleaving
free amino group containing structures,[33] chromophoric
amines[23] after Pro or D-amino acids after Ser or Ala.[34,35]
Homologation at position P1’ has a main effect on the C-
terminal part of the peptide, but since P1’ carbonyl or
interactions of P2’-Pn’ with the enzyme are not prerequisite for
recognition,[36] this retained promiscuity can be explained. While
peptides with Pro or hydroxyproline at position P1’ are resistant
to DPP-4 cleavage,[20,37] interestingly, the cyclic amino acid
containing analog (IP-(1S,2S)ACPC) is not stable. The difference
between the two substitution strategies is that the nitrogen of
ACPC at P1’ can be protonated, which is a requirement for the
serine protease mechanism of DPP-4,[38] thus explaining the
instability of this analog.
The only exception to the broad substrate specificity in our
series of IPβXaa ligands was the substitution with β3Ile, which
resulted in a significantly increased stability, which was not
depending on peptide length, pointing towards that this is a
unique and general effect of the β3Ile substitution. Since the
electronic environment around the α/β-bond is similar in all
tested analogs, one explanation could be the β-branched side
chain. Side-chain branching can have a profound effect on the
local conformation of the peptide,[39] which might result in a
spatial arrangement incompatible with enzyme recognition. To
support this, β3Ile, β3Ala and ACPC containing analogs were
tested in a DPP-4 inhibitory assay. IPA and IPβ3A showed similar
DPP-4 inhibitory activity (Figure S1), whereas analogs having
substitution with β3Ile and ACPC did not inhibit the enzyme as
effectively as their natural counterparts. Thus, slower cleavage is
associated with less inhibitory activity, pointing towards that
these substitutions are detrimental to binding to the enzyme
and including these amino acids in a sequence would provide
stability against DPP-4. Since the side chain of the P1’ amino
acid of the natural sequence IPI is not involved in binding to
the active site of DPP-4[29,36] another explanation could be that
upon substitution a more favorable stabilizing interaction is
formed between the C-terminal amide of the peptide and the
enzyme. This kind of interaction is proposed to stabilize
degradation byproducts by preventing P1’ amino acid leaving
from the active site.[29]
Due to the lack of specificity for β-amino acids at position
P1’ shown here, one could speculate that similar substrates
with penultimate Ser or Ala could also be cleaved. Bai et al.[40]
reported that substitution of glutamic acid after Ala (Glu3) in
GLP-1 molecule with corresponding β-amino acid lead to
increased stability towards DPP-4 degradation and half-life
~96 h. In contrast, the peptide IPβ3E investigated here was
cleaved almost as fast as the natural sequences, pointing
towards this property of DPP-4 might be specific to penultimate
Pro and not Ala. This feature should be further investigated
because mechanism of DPP-4 cleavage is slightly different for
Pro and Ala containing DPP-4 substrates.[23]
Figure 4. Proteinase K degradation curves of LPQNIPPL and LPβ3QNIPPL.
Remaining peptide quantities were determined based on LCMS peak
integration. Peptides (50 μM final concentration) were incubated with
proteinase K (24 μg/mL final concentration) in TBS buffer (pH 8.0) at 37 °C for
24 h. Curves were fitted by using a one-phase exponential decay fit with a
variable plateau value y = (y0–yP)e
  kx +yP. Data points show the average of
two individual experiments, error bars represent the standard deviation. In
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Our findings suggest that care should be taken when
designing α/β-peptide analogs including Pro residues, since all
peptides with penultimate Pro are considered as good sub-
strates for DPP-4.[37] Possible obstacles regarding the proteolytic
stability of such analogs could occur, moreover because DPP-4
is present at the absorption site in gastrointestinal tract and
other tissues, as well as in circulating form, which raises issues
about bioavailability of such peptides. As an example, DPP-4 is
one of the enzymes involved in endomorphin metabolism,[41]
which, together with our findings could explain the degradation
of a previously reported endomorphin analog with α-hydroxy-
β-phenylalanine (AHPBA) substitution at position P1’.[42]
DPP-4 resistant peptide analogs can be created by substitut-
ing amino acid at position P1 with amino acids such as 2-
aminoisobutyric acid (Aib).[43] Here we show that substitution
with the Pro mimicking β-amino acid, ACPC can also result in
highly stable analogs. Thus, using this strategy DPP-4 resistant
analogs can be prepared, assuming that the binding prefer-
ences to the target receptor allow such kind of substitution.
Furthermore, exploiting our findings, a selective proteolytic
profile can be achieved by rational design of the peptide
sequence resulting in cleavage only by DPP-4 and not by other
enzymes, as we have shown for LPQNIPPL and its analog
(Figure 4), or in an opposite way controlled slow cleavage by
DPP-4 can be encoded in the sequence by incorporating β3Ile
residues after Pro.
Conclusion
In summary, we have shown that DPP-4 cleaves α/β-peptide
bond when an α-amino acid after penultimate N-terminal Pro is
replaced with a β3- or constrained (cyclic) β-amino acid, and it
retains its broad substrate specificity and full enzymatic activity
regardless of the chemical properties of the side chain. This
activity is unique compared to other human enzymes involved
in peptide cleavage known so far. The only exception to this is
when β3Ile is present at position P1’ which increases the
stability significantly, thus this replacement can be used to
create analogs stable against DPP-4 cleavage. Cleavage does
not occur either when Pro at position P1 is replaced with ACPC,
which provides an option to generate stable ligands in which
this substitution is tolerated. While Pro or Ala are preferred at
position P1, α/β-peptide analogs containing Ser, Gly, Val and
Leu at this position could also be potentially cleaved.[20,22]
Exploiting these findings, a selective and programmable
proteolytic profile can be designed, leading to a sequence-
controlled degradation pattern, thus extending the scope of the
utilization of α/β-peptides.
Experimental Section
Peptides synthesis, purification and identification. Peptides were
synthesized manually by standard solid-phase peptide synthesis
using Fmoc chemistry. Tentagel S RAM (for peptide IP-(1S,2S)ACPC),
Fmoc-Rink-Amid AM (for peptides IPβG (IPβA), IPβ3K, IPβ3Q and
IPβ3W) and Tentagel R RAM (for all other peptides) resins were used
as a solid supports. Couplings were carried out using 3 equivalent
amino acid excess, COMU (3 equivalent) as a coupling reagent and
DIPEA (3 equivalent) as base for 3 h at room temperature.
Deprotection was carried out using 2% piperidine and 2% DBU
(1,8-diazabicycloundec-7-ene) in DMF (N,N-dimethylformamide).
Peptides were cleaved from the resin using TFA/H2O/DTT/TIS
(90 :5 :2.5 : 2.5) or TFA/H2O (95 :5) for 3 h. After the cleavage, TFA
was evaporated, peptides LPQNIPPL and LPβ3QNIPPL were precipi-
tated in ice-cold diethlyether and re-dissolved in acetic acid, diluted
with water and freeze dried. All other peptides were dissolved after
TFA evaporation without the precipitation step and freeze dried.
Peptides were purified by RP-HPLC on a C18 column (Phenomenex
Luna 5 μm C18(2) 100 Å, 250×10 mm) using 0.1% TFA in water and
0.1% TFA, 80% ACN in water as HPLC eluents. Pure fractions were
pooled together and freeze dried. Purity of the peptides was
confirmed by ESI-MS measurements and analytical RP-HPLC on
Aeris Peptide XB-C18 column (250×4.6 mm). Eluents were A: 0.1%
TFA in water and B: 0.1% TFA, 80% ACN in water using a gradient
of 5–80% B over 15 min at 50 °C at 1.2 mL/min flow rate (for IPβ3K),
0–40% B over 25 min at 50 °C at 1.2 mL/min flow rate (for IPβ3Q
and IPβ3S) and 0–60% B over 25 min at 50 °C at 1.2 mL/min flow
rate (for all other peptides).
Peptides were identified by HPLC-MS on analytical HPLC column
Aeris Peptide XB-C18 (250×4.6 mm). Eluents were A: 0.1% HCOOH
in water and B: 0.1% HCOOH in ACN using a gradient of 5–80% B
over 15 min at 50 °C at 0.7 mL/min flow rate (for IPβ3K), 0–40% B
over 20 min at 50 °C at 0.7 mL/min flow rate (for IPβ3Q and IPβ3S)
and 0–60% B over 20 min at 50 °C at 0.7 mL/min flow rate (for all
other peptides).
DPP-4cleavage protocol. Peptide stock solutions (1 mM) were
prepared by dissolving peptides in 20% DMSO/TBS buffer (45 mM
Tris ·HCl, pH 8.0) and diluted to 500 μM using TBS buffer. DPP-4 was
purchased from Sigma-Aldrich (D3446), supplied as a solution in
45 mM Tris ·HCl, pH 8.0, 124 mM NaCl, 2.4 mM KCl, 225 mM
imidazole, 10% glycerol and 3 mM DTT. From the DPP-4 stock
solution (� 0.01 mg/mL,�4500 units/μg), a diluted enzyme sol-
ution was prepared using 1.7 μL of the stock solution and 110.3 μL
of TBS buffer. Cleavage reactions were performed using 35 μL of
diluted peptide solution (50 μM final concentration), 52.5 μL of
diluted enzyme solution and 262.5 μL of TBS buffer and incubated
at 37 °C for 24 h. Controls containing diluted peptide solution
(50 μM final concentration) without the enzyme in TBS buffer were
also prepared and measured at t =0 and after 24 h. At eight time
points (0, 5, 15, 30, 60, 180, 360 and 1440 min), an aliquot of 20 μL
was removed from the incubation mixtures and pipetted into 80 μL
of 5% TFA solution to quench the reaction, from which 20 μL was
injected to the HPLC. All samples were prepared in duplicates. The
amounts of intact peptides and DPP-4 cleavage products at
selected time points were analyzed by HPLC-MS.
Proteinase K cleavage protocol. Peptide stock solutions (1 mM)
were prepared by dissolving peptides in DMSO and diluted to
100 μM using TBS buffer (50 mM Tris ·HCl, 5 mM CaCl2, pH 8.0).
Proteinase K stock solution (5 mg/mL) was prepared in 20%
glycerol/TBS, which was further diluted to 120 μg/mL in TBS buffer.
Cleavage reactions were performed using 550 μL of diluted peptide
solution (50 μM final concentration), 220 μL of diluted enzyme
solution (24 μg/mL final concentration) and 330 μL of TBS buffer
and incubated at 37 °C for 24 h. Controls containing diluted peptide
solution (50 μM final concentration) without the enzyme in TBS
buffer were also prepared and measured at t =0 and after 24 h. At
eight time points (0, 5, 15, 30, 60, 180, 360 and 1440 min), an
aliquot of 50 μL was removed from the incubation mixtures and
pipetted into 100 μL of 5% TFA solution to quench the reaction,
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prepared in duplicates. The amounts of intact peptides and
proteinase K cleavage products at selected time points were
analyzed by HPLC-MS.
HPLC-MS methods and parameters for identification of intact
peptides and cleavage products. HPLC-MS analysis was performed
on a Thermo Scientific Dionex UltiMate 3000 HPLC system
interfaced to LTQ ion trap mass spectrometer (Thermo Electron
Corp., San Jose, CA, USA). Measurements were performed using
analytical HPLC column Aeris Widepore XB-C18 (250×4.6 mm) with
0.1% HCOOH in water and 0.1% HCOOH in ACN as HPLC eluents.
Operating conditions were 0–60% ACN over 20 min at 50 °C and 0–
40% ACN over 20 min at 50 °C (for peptides IPβ3K, IPβ3Q and IPβ3S)
at 0.7 mL/min flow rate. Mass spectra were acquired in a positive
ion full scan mode from 110 to 2000 m/z range.
HPLC-MS quantification of intact peptides and cleavage products.
Thermo Xcalibur 2.2 software was used for peak identification and
integration. Using ICIS peak detection algorithm, the general
detection and integration criteria were as follows – smoothing
points: 5–15, baseline window: 50, area noise factor: 5, peak noise
factor: 10.
Intact peptides and DPP-4/Proteinase K cleavage products were
identified based on their molecular weights and retention times,
thereafter areas under the curves (AUC) were determined. The
percentage of the intact peptides at each of the time points was
determined using the following equation [Eq. (1)]:
intact peptide ð%Þ ¼ AUCt=AUCt0 � 100 (1)
where AUCt is the area under the curve at a specific time point and
AUCt0 area under the curve at t =0. The % of intact peptide IPβ
3K
was calculated based on the amount of cleavage product IP using
the following equation: 100 – (AUCIP,t/AUCIP,6h×100), with the
assumption that the peptide is fully cleaved after 6 h. The
percentages of the remaining intact peptides were plotted against
time in order to assess the half-life values based on the fitted
curves. The data was fitted to one-phase exponential decay fit with
a variable plateau value y = (y0–yP)e
  kx + yP using GraphPad Prism to
generate a calculated half-life.
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